Unknown

Dataset Information

0

Stability Studies of the Vaccine Adjuvant U-Omp19.


ABSTRACT: Unlipidated outer membrane protein 19 (U-Omp19) is a novel mucosal adjuvant in preclinical development to be used in vaccine formulations. U-Omp19 holds two main properties, it is capable of inhibiting gastrointestinal and lysosomal peptidases, increasing the amount of co-administered antigen that reaches the immune inductive sites and its half-life inside cells, and it is able to stimulate antigen presenting cells in vivo. These activities enable U-Omp19 to enhance the adaptive immune response to co-administrated antigens. To characterize the stability of U-Omp19 we have performed an extensive analysis of its physicochemical and biological properties in a 3-year long-term stability study, and under potentially damaging freeze-thawing and lyophilization stress processes. Results revealed that U-Omp19 retains its full protease inhibitor activity, its monomeric state and its secondary structure even when stored in solution for 36 months or after multiple freeze-thawing cycles. Non-enzymatic hydrolysis resulted the major degradation pathway for storage in solution at 4 °C or room temperature which can be abrogated by lyophilization yet increasing protein tendency to form aggregates. This information will play a key role in the development of a stable formulation of U-Omp19, allowing an extended shelf-life during manufacturing, storage, and shipping of a future vaccine containing this pioneering adjuvant.

SUBMITTER: Darriba ML 

PROVIDER: S-EPMC7815325 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Stability Studies of the Vaccine Adjuvant U-Omp19.

Darriba M Laura ML   Cerutti María L ML   Bruno Laura L   Cassataro Juliana J   Pasquevich Karina A KA  

Journal of pharmaceutical sciences 20201012 2


Unlipidated outer membrane protein 19 (U-Omp19) is a novel mucosal adjuvant in preclinical development to be used in vaccine formulations. U-Omp19 holds two main properties, it is capable of inhibiting gastrointestinal and lysosomal peptidases, increasing the amount of co-administered antigen that reaches the immune inductive sites and its half-life inside cells, and it is able to stimulate antigen presenting cells in vivo. These activities enable U-Omp19 to enhance the adaptive immune response  ...[more]

Similar Datasets

| S-EPMC5313482 | biostudies-literature
| S-EPMC3881025 | biostudies-literature
2024-08-01 | GSE239649 | GEO
| S-EPMC6333709 | biostudies-literature
2024-08-01 | GSE239646 | GEO
2024-08-01 | GSE239643 | GEO
| S-EPMC3108434 | biostudies-literature
| S-EPMC6941222 | biostudies-literature
| PRJNA1000475 | ENA
| S-EPMC3491477 | biostudies-literature